First-in-human study of PF-06647020 (cofetuzumab pelidotin), an antibody-drug conjugate targeting protein tyrosine kinase 7, in advanced solid tumors

Michael L. Maitland, Jasgit C. Sachdev, Manish R. Sharma, Victor Moreno, Valentina Boni, Shivaani Kummar, Erica Stringer-Reasor, Nehal Lakhani, Allison R. Moreau, Dawei Xuan, Ray Li, Eric L. Powell, Amy Jackson-Fisher, Michelle Bowers, Shilpa Alekar, Xiaohua Xin, Anthony W. Tolcher, Emiliano Calvo

Research output: Contribution to journalArticlepeer-review

40 Scopus citations


Purpose: We investigated safety, tolerability, pharmacokinetics, and antitumor activity of the protein tyrosine kinase 7 (PTK7)targeted, auristatin-based antibody-drug conjugate (ADC) PF-06647020/cofetuzumab pelidotin (NCT02222922). Patients and Methods: Patients received PF-06647020 intravenously every 3 weeks at 0.2-3.7 mg/kg or every 2 weeks at 2.1-3.2 mg/kg, in sequential dose escalation, following a modified toxicity probability interval method. In dose expansion, pretreated patients with advanced, platinum-resistant ovarian cancer, non-small cell lung cancer (NSCLC), or triple-negative breast cancer (TNBC) received PF-06647020 2.8 mg/kg every 3 weeks. Results: The most common, treatment-related adverse events for PF-06647020 administered every 3 weeks were nausea, alopecia, fatigue, headache, neutropenia, and vomiting (45%-25%); 25% of patients had grade ≥ 3 neutropenia. Two patients experienced dose-limiting toxicities (grade 3 headache and fatigue) at the highest every 3 weeks dose evaluated. The recommended phase II dose was 2.8 mg/kg every 3 weeks. The overall safety profile observed with PF-06647020 administered every 2 weeks was similar to that of the every 3 weeks regimen. Systemic exposure for the ADC and total antibody generally increased in a dose-proportional manner. Antitumor activity was observed in treated patients with overall objective response rates of 27% in ovarian cancer (n = 63), 19% in NSCLC (n = 31), and 21% in TNBC (n = 29). Responders tended to have moderate or high PTK7 tumor expression by IHC. Conclusions: This PTK7-targeted ADC demonstrated therapeutic activity in previously treated patients with ovarian cancer, NSCLC, and TNBC at a dose range of 2.1-3.2 mg/kg, supporting further clinical evaluation to refine dose, schedule, and predictive tissue biomarker testing in patients with advanced malignancies.

Original languageEnglish (US)
Pages (from-to)4511-4520
Number of pages10
JournalClinical Cancer Research
Issue number16
StatePublished - Aug 15 2021
Externally publishedYes

ASJC Scopus subject areas

  • General Medicine


Dive into the research topics of 'First-in-human study of PF-06647020 (cofetuzumab pelidotin), an antibody-drug conjugate targeting protein tyrosine kinase 7, in advanced solid tumors'. Together they form a unique fingerprint.

Cite this